Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
Clinical trial NCT06662006 · RECRUITING
Trial details
- NCT number
- NCT06662006
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-01
- Primary completion
- 2027-12-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.